I dont think I will ever buy P

2023-06-09

I dont think I will ever buy Pfizer, for ideological reasons, if there is such a thing. In fact I am not sure if its possible to discuss all potential downsides openly, which seems to be weird as economy should value rational decision making, however the crowd might be driven by animal instincts.

2 Unstoppable Stocks to Buy Before the Bull Market

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":185175867199592,"tweetId":"185175867199592","gmtCreate":1686248231759,"gmtModify":1686248235935,"author":{"id":4147085113828402,"idStr":"4147085113828402","authorId":4147085113828402,"authorIdStr":"4147085113828402","name":"clouddragon","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.29","exceedPercentage":"80.97%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>I dont think I will ever buy Pfizer, for ideological reasons, if there is such a thing. In fact I am not sure if its possible to discuss all potential downsides openly, which seems to be weird as economy should value rational decision making, however the crowd might be driven by animal instincts.</p></body></html>","htmlText":"<html><head></head><body><p>I dont think I will ever buy Pfizer, for ideological reasons, if there is such a thing. In fact I am not sure if its possible to discuss all potential downsides openly, which seems to be weird as economy should value rational decision making, however the crowd might be driven by animal instincts.</p></body></html>","text":"I dont think I will ever buy Pfizer, for ideological reasons, if there is such a thing. In fact I am not sure if its possible to discuss all potential downsides openly, which seems to be weird as economy should value rational decision making, however the crowd might be driven by animal instincts.","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/185175867199592","repostId":2341587129,"repostType":2,"repost":{"id":"2341587129","pubTimestamp":1686211500,"share":"https://www.laohu8.com/m/news/2341587129?lang=&edition=full","pubTime":"2023-06-08 16:05","market":"us","language":"en","title":"2 Unstoppable Stocks to Buy Before the Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2341587129","media":"Motley Fool","summary":"Investors should expect both of these businesses to get even bigger in the years ahead.","content":"<html><head></head><body><h2 style=\"text-align: start;\">KEY POINTS</h2><ul><li><p>Demand for Palantir&#39;s products is through the roof as AI unlocks a huge new growth catalyst.</p></li><li><p>Pfizer has been on an acquisition spree over the past few years as it looks to grow and diversify.</p></li></ul><p>The market has been showing signs of life this year, but the <strong>S&amp;P 500</strong> remains down 10% since peaking in 2022. In a full-blown bull market, many businesses could see their valuations skyrocket, particularly those that are focused on growth. And a couple of unstoppable companies that investors may want to buy before that happens are <strong>Palantir Technologies </strong>and <strong>Pfizer</strong>.</p><h2>1. Palantir Technologies</h2><p>Palantir Technologies has been a hot stock lately, soaring more than 130% since the start of 2023. Artificial intelligence (AI) and the potential growth opportunities that it can open up for Palantir are what have been driving a lot of the recent bullishness for the business.</p><p>The company specializes in data analytics and helping both businesses and government agencies make quicker and better decisions. If AI can accelerate and improve that data analysis, that can enhance Palantir&#39;s offerings and improve its efficiency. It has recently launched a new product, Artificial Intelligence Platform (AIP), which promises to &#34;build everything faster with human-AI collaboration.&#34; And demand has been taking off.</p><p>In a recent interview with Bloomberg, CEO Alex Karp said that the company has customers in the U.S. who are &#34;calling us every day&#34; and that it has received a year&#39;s worth of inbound calls within about a month.</p><p>If those elevated activity levels translate into significant sales growth, Palantir could be on the verge of reporting some impressive numbers this year. In 2022, revenue of $1.9 billion rose by 24%. And that&#39;s with the company&#39;s growth rate slowing down.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/233b6f43ef1d32882987d95b85ad034e\" alt=\"PLTR Revenue (Annual YOY Growth) data by YCharts\" title=\"PLTR Revenue (Annual YOY Growth) data by YCharts\" tg-width=\"720\" tg-height=\"433\"/><span>PLTR Revenue (Annual YOY Growth) data by YCharts</span></p><p>While the stock may seem like it&#39;s already a bit too hot to buy right now, shares of Palantir are still down close to 20% since the beginning of 2022.</p><p>Management is now expecting profitability to be the norm, and that could be an additional catalyst for Palantir. The company is not slowing down -- in fact, it looks to be shifting into a higher gear. In a bull market, where investors are more willing to pay a premium for a growing business, Palantir could become an even hotter buy.</p><p>That&#39;s why if you&#39;re willing to hold on to the stock for multiple years, Palantir could be an attractive investment to buy and hold today.</p><h2>2. Pfizer</h2><p>Unfortunately, there isn&#39;t nearly as much bullishness about Pfizer these days. The healthcare stock remains around its 52-week low, and its price-to-earnings multiple of less than 8 suggests more than just a healthy dose of skepticism from investors. The company benefited from its highly effective and popular COVID-19 vaccine, which helped it generate record-breaking sales last year, topping more than $100 billion.</p><p>Investors are now concerned about Pfizer&#39;s future because it may be a long time before it gets back to those levels again. The government is no longer loading up on vaccines now that the public health emergency relating to COVID is over.</p><p>But Pfizer is already looking past that and has been involved in multiple acquisitions over the past few years in an effort to set up its business for longer-term growth to offset the impact of declining COVID revenue, as well as an inevitable drop in sales as multiple drugs lose patent protection this decade.</p><p>Pfizer&#39;s biggest plans involve expanding its presence in oncology. In March, the drugmaker announced that it wants to buy biotech <strong><a href=\"https://laohu8.com/S/SGEN\">Seagen</a> </strong>for $43 billion. Prior to that, Pfizer closed on acquisitions of Global Blood Therapeutics, Biohaven Pharmaceuticals, Arena Pharmaceuticals, and ReViral in 2022.</p><p>Pfizer is coming off a couple of years of strong free cash flow generation, which has bolstered its financial position. And as of April 2, the company still had around $20 billion in cash and short-term investments on its books, meaning that it still has the ability to pursue more deals if necessary.</p><p>Robust financial resources ensure that the company&#39;s quest to get stronger and more diversified will continue. Pfizer is another unstoppable-looking business that may be worth investing in right now, especially with its price being relatively low and offering investors a good margin of safety.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Unstoppable Stocks to Buy Before the Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Unstoppable Stocks to Buy Before the Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-08 16:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/06/07/2-unstoppable-stocks-to-buy-before-the-bull-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSDemand for Palantir's products is through the roof as AI unlocks a huge new growth catalyst.Pfizer has been on an acquisition spree over the past few years as it looks to grow and diversify....</p>\n\n<a href=\"https://www.fool.com/investing/2023/06/07/2-unstoppable-stocks-to-buy-before-the-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4007":"制药","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","PLTR":"Palantir Technologies Inc.","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","PFE":"辉瑞","BK4097":"系统软件","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4581":"高盛持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus"},"source_url":"https://www.fool.com/investing/2023/06/07/2-unstoppable-stocks-to-buy-before-the-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2341587129","content_text":"KEY POINTSDemand for Palantir's products is through the roof as AI unlocks a huge new growth catalyst.Pfizer has been on an acquisition spree over the past few years as it looks to grow and diversify.The market has been showing signs of life this year, but the S&P 500 remains down 10% since peaking in 2022. In a full-blown bull market, many businesses could see their valuations skyrocket, particularly those that are focused on growth. And a couple of unstoppable companies that investors may want to buy before that happens are Palantir Technologies and Pfizer.1. Palantir TechnologiesPalantir Technologies has been a hot stock lately, soaring more than 130% since the start of 2023. Artificial intelligence (AI) and the potential growth opportunities that it can open up for Palantir are what have been driving a lot of the recent bullishness for the business.The company specializes in data analytics and helping both businesses and government agencies make quicker and better decisions. If AI can accelerate and improve that data analysis, that can enhance Palantir's offerings and improve its efficiency. It has recently launched a new product, Artificial Intelligence Platform (AIP), which promises to \"build everything faster with human-AI collaboration.\" And demand has been taking off.In a recent interview with Bloomberg, CEO Alex Karp said that the company has customers in the U.S. who are \"calling us every day\" and that it has received a year's worth of inbound calls within about a month.If those elevated activity levels translate into significant sales growth, Palantir could be on the verge of reporting some impressive numbers this year. In 2022, revenue of $1.9 billion rose by 24%. And that's with the company's growth rate slowing down.PLTR Revenue (Annual YOY Growth) data by YChartsWhile the stock may seem like it's already a bit too hot to buy right now, shares of Palantir are still down close to 20% since the beginning of 2022.Management is now expecting profitability to be the norm, and that could be an additional catalyst for Palantir. The company is not slowing down -- in fact, it looks to be shifting into a higher gear. In a bull market, where investors are more willing to pay a premium for a growing business, Palantir could become an even hotter buy.That's why if you're willing to hold on to the stock for multiple years, Palantir could be an attractive investment to buy and hold today.2. PfizerUnfortunately, there isn't nearly as much bullishness about Pfizer these days. The healthcare stock remains around its 52-week low, and its price-to-earnings multiple of less than 8 suggests more than just a healthy dose of skepticism from investors. The company benefited from its highly effective and popular COVID-19 vaccine, which helped it generate record-breaking sales last year, topping more than $100 billion.Investors are now concerned about Pfizer's future because it may be a long time before it gets back to those levels again. The government is no longer loading up on vaccines now that the public health emergency relating to COVID is over.But Pfizer is already looking past that and has been involved in multiple acquisitions over the past few years in an effort to set up its business for longer-term growth to offset the impact of declining COVID revenue, as well as an inevitable drop in sales as multiple drugs lose patent protection this decade.Pfizer's biggest plans involve expanding its presence in oncology. In March, the drugmaker announced that it wants to buy biotech Seagen for $43 billion. Prior to that, Pfizer closed on acquisitions of Global Blood Therapeutics, Biohaven Pharmaceuticals, Arena Pharmaceuticals, and ReViral in 2022.Pfizer is coming off a couple of years of strong free cash flow generation, which has bolstered its financial position. And as of April 2, the company still had around $20 billion in cash and short-term investments on its books, meaning that it still has the ability to pursue more deals if necessary.Robust financial resources ensure that the company's quest to get stronger and more diversified will continue. Pfizer is another unstoppable-looking business that may be worth investing in right now, especially with its price being relatively low and offering investors a good margin of safety.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":245,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/185175867199592"}